Athena Athena

X
[{"orgOrder":0,"company":"Globe Biotech Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Globe Biotech's BANCOVID Elicits Neutralizing Antibody and Balanced Cellular Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BANGLADESH","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Globe Biotech Limited

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The candidate mRNA vaccine ‘BANCOVID’ is a LNP–encapsulated, nucleoside-modified mRNA–based vaccine that encodes the SARS-CoV-2 spike (S) glycoprotein stabilized in its prefusion conformation.

            Lead Product(s): D614G variant LNP-encapsulated mRNA

            Therapeutic Area: Infections and Infectious Diseases Product Name: Bancovid

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY